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Abstract 
 
The purpose of this research was to develop anti-cytokine-based treatment using extract of Plectranthus amboinicus 
applied to gout arthritis (GA) patients. The research was quasi experimental, with a pretest-posttest randomized control 
group design. The samples were GA patients in the Outpatient Installation of Internal Medicine in General Hospital 
Haji, Surabaya. The sample was comprised of 30 respondents. The respondents were divided into a treatment group and 
a control group. The treatment group was asked to take medicine from the hospital, coupled with P. amboinicus extract 
capsules, for 7 days, during which time patients’ joint inflammation was observed. The control group was provided with 
only medication from the hospital, and their joint inflammation was likewise observed. Blood samples were taken 
before and after treatment, to measure the levels of blood urea nitrogen (BUN) and creatinine, as well as the 
concentrations of TNF-α and IL-1β. There was a decrease in BUN and creatinine levels in the control group, but it was 
not significant, decreasing by 3% and 8%, respectively. The treatment group also showed elevated levels of BUN and 
creatinine, which also was not significant at 3% and 7%, respectively. There was a decrease in the concentration of 
TNF-α in the control group by 9% and 22%. The concentration of IL-1β in the control group increased by 18%, 
whereas,in the treatment group, it decreased by 3%; however, the decreases in both groups were not significant. 
 
 
Abstrak 
 
Pengaruh Ekstrak Daun Jintan (Plectranthus amboinicus) terhadap Kadar BUN dan Kreatinin serta Respon 
Seluler Faktor Proinflamasi TNF-α dan IL-1β Pasien Gout Artritis. Pengobatan gout artritis (GA) saat ini 
dikembangkan berbasis anti sitokin yaitu blokade kemokin, penghambatan pelepasan IL-1β dan TNF-α. Tujuan 
penelitian ini adalah mengembangkan pengobatan berbasis anti sitokin dengan menggunakan ekstrak daun jintan yang 
diaplikasikan pada penderita GA. Penelitian ini adalah penelitian eksperimental semu dengan desain penelitian 
randomized pretest-posttest control group design. Pengambilan sampel pasien GA di Instalasi Rawat Jalan Poli 
Penyakit Dalam RSU Haji Surabaya yang memenuhi kriteria inklusi dan eksklusi. Jumlah sampel sebanyak 30 
responden terbagi menjadi kelompok perlakuan dan kelompok kontrol masing-masing 15 responden. Pada kelompok 
perlakuan diminta untuk minum obat dari Rumah Sakit ditambah dengan kapsul ekstrak daun jintan selama 7 hari, 
dengan dilakukan pengamatan keradangan sendi. Pada kelompok kontrol minum obat dari Rumah Sakit dan dilakukan 
pengamatan keradangan sendi. Sampel darah diambil sebelum dan sesudah perlakuan untuk mengukur kadar BUN, 
kreatinin, konsentrasi TNF-α dan IL-1β. Terdapat penurunan kadar BUN dan kreatinin pada kelompok kontrol namun 
tidak signifikan yaitu menurun sebesar 3% dan 8%. Sementara pada kelompok perlakuan terdapat peningkatan kadar 
BUN dan Kreatinin namun juga tidak signifikan sebesar 3% dan 7%. Terdapat penurunan konsentrasi TNF-α pada 
kelompok kontrol sebesar 9% dan kelompok perlakuan sebesar 22%, keduanya tidak signifikan. Sementara konsentrasi 
IL-1β terjadi peningkatan pada kelompok kontrol sebesar 18%, sementara pada kelompok perlakuan terjadi penurunan 
sebesar 3%, keduanya tidak signifikan. 
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Introduction 
 
On the occurrence of gout arthritis (GA), acute 
symptoms are easily observed in the form of disruptive 
pain in the joint, which requires prompt treatment to 
control pain and inflammation. GA symptoms are 
caused by a complex inflammatory reactions involving 
the proinflammatory factors TNF-α and interleukin-
1β.1,2 The emergence of GA is acutely stimulated by 
trauma, surgery, and the consumption of alcohol and 
certain drugs that alter serum urate levels. High levels of 
urate are distributed to various tissues, and deposition of 
urea crystals in the joints cancauserecurrent acute 
inflammation. In appropriate treatment can lead to 
chronic inflammation, can cause urea crystals to form 
tophi deposition (tophi gout), and cause structural 
damage in joints. In cases of continued chronic 
polyarthritis, other tissues will be affected, such as 
kidney (nephropathy and uric acid nephrolithiasis), 
juxta-articular, cardiac, and subcutaneous tissue.2 
 
The deposition of ureacrystals into the renal tubules will 
interfere with the function of kidney filtration, and it can 
be detected by increasing levels of blood urea nitrogen 
(BUN) and creatinine concentrations. Therefore, it can 
be used as initial parameters for analyzing the condition 
of the kidney filtration function. Increased BUN and 
creatinine may occur simultaneously or, sometimes, 
creatinine levels will increase while the BUN level 
rises, when kidney damage has reached 60%.3 
 
Plectranthus amboinicus belongs to the family 
Lamiaceae, once identified as Coleus amboinicus, and, 
in Indonesia, as daun bangun bangun. This plant has 
been used traditionally as food, and as herbal remedies, 
especially to cure various diseases. The chemical 
composition of P. amboinicus in the form of ethanol 
extract consists of flavonoids, saponins, polyphenols, 
essential oils, and Antrakuinon.4 
 
Existing treatments for GA are symptomatic, blocking 
only the formation of leukotrienes and prostaglandins in 
the inflammatory process, without eliminating the major 
cause.5 However, long-term use of these anti-
inflammatory drugs potentially damages kidney and 
liver function.6 
 
The current treatment of GA was developed based on 
the anti-cytokine chemokine blockade,7 inhibition of IL-
1β,8 and TNF-α inhibition.9-11 Anti-cytokine-based 
treatment is more effective against the main causes GA 
than symptomatic treatment is. Several studies has 
shown that use of P. amboinicus leaf extract has 
inhibitory effects on anti-cytokine release in induced 
inflammation in mice.12 However, research on 
applications of P. amboinicus leaf extract for the 
development of anti-cytokine-based treatment for 
patients with GA has not been done. This study aims to 
analyze the effect of P. amboinicus leaf extract in 
patients with GA, by measuring the levels of BUN, 
creatinine, TNF-α and IL-1β, before and after treatment 
in the treatment group and the control group. 
 
Methods 
 
A quasi-experimental research method was used in the 
study, to provide treatment for patients with GA. The 
study design was a randomized pretest-posttest control 
group design with single blind administration. 
 
Sample criteria. The subjects of this study were 
patients with GA in the Outpatient Installation of 
Internal Medicine in the General Hospital (RSU) Haji, 
Surabaya, who met the inclusion criteria,being diagnosed 
with GA (established in accordance with specific clinical 
symptoms) and agreeing to follow the research by 
completing the informed consent, and the exclusion 
criteria, no history of gastritis, duodenal ulcer, 
hypersensitivity to the drugs indomethacin and P. 
amboinicus, and not a pregnant or lactating woman. The 
exclusion criteria were used to restrict the study group 
and reduce the risk of treatment interventions. These 
data were derived from the results of the interview and 
physical examination by the doctor; however, participants 
did not require detailed examination. Indomethacin 
served as the drug of choice of GA patients. 
 
Clinical research. The sample consisted of 30 
respondents. The respondents were grouped into one of 
two groups: 15 in the treatment group and 15 in the 
control group. Blood samples of respondents were taken 
to measure levels of BUN, creatinine, TNF-α, and IL-1β 
as the initial data before the treatment. Those in the 
treatment group were asked to take standard medication 
from the hospital, coupled with P. amboinicus leaf 
extract capsules for 7 days, 1 capsule daily, and they 
underwent observation of the inflammation in the joints. 
Those in the control group were provided only the 
standard medication from hospital and the inflammation 
of their joints was observed. After 7 days, in each 
group, blood sample were collected to test the levels of 
BUN, creatinine, TNF-α, and IL-1β. Then the results 
were analyzed to determine differences in the levels of 
BUN, creatinine, TNF-α, and IL-1β, before and after 
treatment, between the treatment group and the control 
group. 
 
Ethical clearance. This study was approved by the 
Ethical Committee of General Hospital Haji, Surabaya, 
No. 073/18/KOM.ETIK/2013. Blood samples were 
collected by experienced medical personnel (nurses of 
General Hospital Haji, Surabaya). 
 
Data analysis techniques. Blood samples were tested 
to determine the concentration of BUN, creatinine, 
TNF-α, and IL-1β. Measurements of TNF-α and IL-1β 
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concentrations were obtained by using the Elisa 
technique. Paired sample t-tests (paired t-test) were 
employed to determine the significance level of the 
differences in BUN, creatinine, TNF-α, and IL-1β 
concentrations before and after the treatment. 
 
Results and Discussion 
 
Clinical Research. Preparation of P. amboinicus leaf 
extracts was done in Integrated Research and Testing 
Laboratory (Laboratorium Penelitian dan Pengujian 
Terpadu/LPPT Universitas Gadjah Mada/UGM). It was 
prepared into capsules using pharmaceutical technology 
at a dose corresponding to a daily intake of fresh P. 
amboinicus leaves in humans is 210 g/70 kg body 
weight. Leaf extract capsulation was carried out in the 
laboratory of the pharmacology and clinical pharmacy 
UGM. Levels of BUN and creatinine measurements 
were performed in the Clinical Laboratory “Klinika” 
Surabaya. Analysis of the cellular response of TNF-α 
and IL-1β were conducted in the laboratories of the 
Institute for Tropical Diseases (ITD) Universitas 
Airlangga. 
 
BUN and creatinine levels. The following Figure 1 
shows the concentrations of BUN and creatinine in both 
group before and after treatment. 
 
1515N =
PERLAKUA
kontrolperlakuan
BU
N
1
30
20
10
0
20
 
1515N =
PERLAKUA
kontrolperlakuan
BU
N
2
40
30
20
10
0
 
 
1515N =
PERLAKUA
kontrolperlakuan
CR
EA
T1
3.5
3.0
2.5
2.0
1.5
1.0
.5
28
10
4
13
 
1515N =
PERLAKUA
kontrolperlakuan
CR
EA
T2
6
5
4
3
2
1
0
28
10
4
13
 
 
Figure 1.  Boxplot of BUN and Creatinine Concentrations 
of Both Groups of Patients Before and After 
Treatment 
The results of the measurement of BUN and creatinine 
(mg/dl) levels in both group before and after treatment 
are shown in Table 1. 
 
Normal levels of BUN in adults are between 14 and 23 
mg/dL, whereas normal creatinine levels are between 
0.7 and 1.3 mg/dL.13 In the control group, there were 
decreases in creatinine levels by 8%, and, in BUN 
levels, by 3% before and after treatment. In the 
treatment group, BUN and creatinine concentrations 
increased by 3% and 7%, respectively, before and after 
treatment. The results of the statistical analysis in the 
control group showed a decrease in the levels of BUN 
and creatinine, but these were not significant (p> 0.05). 
Meanwhile, there was an increase in BUN and 
creatinine levels in the treatment group, but, likewise, 
the increase was not significant (p> 0.05). 
 
BUN and creatinine concentration are blood chemistry 
parameters used to analyze the normality of kidney 
filtration. The mean concentrations of BUN and 
creatinine from blood samples taken from the entire 
group of patients remained at the normal level. This 
result shows that the patients in this study did not have 
the impaired renal function associated with GA. 
Increasing BUN and creatinine may be indicative of a 
disturbance in the renal filtration both in tubules and 
glomeruli. Increaments of BUN and creatinine may 
occur simultaneously. In addition, the creatinine and the 
BUN levels will rise when kidney damage has reached 
60%.3 
 
Following the administration of P. amboinicus leaf 
extract and standard drug in the treatment group and 
only standard drug administration in the control group, 
no changes in BUN and creatinine levels were shown. 
The results might have occured because the GA patients 
in the study had relatively normal kidney function. In 
the case of continued GA, deposition of urea crystals 
will enter into the kidney tissue, filling the tubular 
lumen, and, thereby, interfering with the function of 
filtration and the absorption of body fluids.2,14,15,16 
 
Concentrations of IL-1β and TNF-α.The results of the 
concentration of IL-1β and TNF-α in all groups of GA 
patients before and after treatment is shown in Figure 2. 
 
The mean concentration of IL-1β and TNF-α in the 
treatment group and the control group of patients before 
 
Table 1.  Mean Concentrations of BUN and Creatinine in 
Both Groups of GA Patients Before and After 
Treatment in the RSU Haji, Surabaya, in 2013 
 
Time Control Group Treatment Group 
 
BUN Creatinine BUN Creatinine 
Before 18.58 1.54 18.08 1.66 
After 17.97 1.42 18.71 1.78 
p 0.667 0.158 0.678 0.505 
Muniroh, et al. 
Makara J. Health Res.  December 2014 | Vol. 18 | No. 3 
116 
1515N =
PERLAKUA
kontrolperlakuan
IL
1
40
30
20
10
0
-10
5
13
12
 
1515N =
PERLAKUA
kontrolperlakuan
IL
2
40
30
20
10
0
-10
5
13
12
 
1515N =
PERLAKUA
kontrolperlakuan
TN
F1
1000
800
600
400
200
0
-200
5
13
12
 
1515N =
PERLAKUA
kontrolperlakuan
TN
F2
700
600
500
400
300
200
100
0
-100
5
12
 
 
Figure 2.  Boxplot of IL-1β and TNF-α Concentrations in 
the Whole Group of GA Patients Before and 
After Treatment 
 
 
and after treatment in the RSU, Haji, Surabaya, is 
described in Table 2. 
 
In the control group, there were increased levels of IL-
1β by 18%, but these were not significant (p> 0.05), 
whereasin the treatment group, it decreased 3% before 
and after treatment, which was also not significant. 
Table 2 also shows a decrease in the concentration of 
TNF-α in the control group by 9%, although it was not 
significant (p> 0.05), whereas there wasa decrease of 
TNF-α by 22% in the treatment group. 
 
The analysis of IL-1β secretion and TNF-α in the 
control group showed increased concentration levels of 
IL-1β and decreased TNF-α concentrations levels before 
and after treatment. These results indicate that the 
administration of the non-steroidal anti-inflammatory 
drug (NSAID) indomethacin may reduce the occurrence 
of inflammation in patients with GA. More over, 
partially marked changes in TNF-α level were lower 
after treatment, but it was not followed by a decrease in 
the levels of IL-1β. Target non-steroidal anti-
inflammatory drugs are blocking the secretion of 
prostaglandin (PGF2-α) and leukotrienes in the 
inflammatory process6; therefore, the secretions of good 
TNF-α sitokine and IL-1β are not dependent on the 
administration of NSAIDs, but they do inhibit migration 
neutrofil.17 Meanwhile, the treatment group showed a 
decline in the level of secretion of IL-1β by 3% and 
decreased  levels  of  TNF-α  secretion  by  22%  after  
Table 2.  The Mean Concentration of IL-1β in Both the 
Treatment and Control Group of GA Patients 
Before and After Treatment in the RSU, Haji, 
Surabaya, in 2013 
 
Time Control Group Treatment Group 
 
IL-1 β TNF-α IL-1 β TNF-α 
Before 9.231 517.125 8.84 478.5 
After 10.982 470.625 8.603 372.166 
p 0.914 0.627 0.497 0.832 
 
 
treatment with P. amboinicus leaf extract capsules and 
standard medication. The decline in the level of IL-1β 
and TNF-α secretion showed that the GA inflammation 
inhibition mechanism was different from that of the 
model of inhibition by NSAIDs. It can be assumed that 
the leaf extract of P. amboinicus contributes in reducing 
the level of cytokines IL-1β and TNF-α that is not 
shown in the control group of patients with NSAIDs. 
 
The GA disease process begins when an increase in the 
level of monosodium urate crystals (MSU), which are 
further distributed into tissues and joints, causing acute 
inflammation mediated by many factors and 
proinflammatory sitokine. In acute GA, inflammatory 
processes involving cell activation endhothelia 
(intercelluler adhesion molecule-1 (ICAM-1) and 
vascular cell adhesion molecule-1 (VCAM-1)) induced 
by TNF-α sitokine and IL-1β. In addition, acute GA 
inflammation occurs due to vasodilatation, increased 
blood flow, increased permeability of plasma proteins, 
and secretion of leukocytes into the tissues.2,18 
 
In both groups, all patients after treatment for 7 days, 
either with NSAIDs (control) and with leaf extract 
(treatment) showed improvement of the inflammation of 
GA,as stated by patients at the beginning of the 
examination. The P. amboinicus leaf extract group was 
not shown to be significantly statistically different (p> 
0.05) in reducing the levels of TNF-α and IL-1β, but 
there wasa decrease in the percentage TNF-α and IL-1β 
concentration of post-treatment compared with the 
control group (treated with NSAIDs) that did not 
decrease IL-1β. The inflammatory process in patients 
with GAin both the treatment and control groups 
clinically did not have the same degree of severity, as it 
can be seen from the variations in symptoms of GA, 
both the level of pain and the swelling ofthe joints. 
Conditions related to nutrition, diet, and the severity of 
the inflammation of GA may affect the healing process 
and the secretion of proinflammatory factors that follow 
the occurrence of GA in patients. 
 
In the case of GA, the inflammation process that occurs 
is mediated by complex secretion of proinflammatory 
factors and sitokine. The classical inflammatory process 
in GA occurs in multiple pathways including phagoly-
sosomes, inactivation of neutrophils, complement 
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activation, bradykinin and kallikrein, and activation of 
eicosanoids, free radicals and TNF-α sitokine and IL-1β 
2,18
 and induction of Toll-like receptor (TLR) -2 ligands 
that activate IL-1β inflammasome.19-22 With a variety of 
pathways and the activation of proin-flammatory factors 
in GA, cytokine secretion of IL-1β has a vital role in 
mediating the inflammation of complex inflammatory 
inflammasome.23 Therefore, appropriate treatment of 
inflammation in GA is targeted at the inhibition of IL-
1β secretion.8,24,25 
 
Anti-cytokine-based treatment promises more effective 
therapies than the symptomatic treatment to eliminate 
the main causes of GA. The group treated with leaf 
extract capsules combined with standard medication 
showed decreased levels of TNF-α secretion by 22%, 
and IL-1β secretion decline by 3% post-treatment. The 
control group treated with standard medication 
(NSAIDs) increased IL-1β by 18%. The results show 
that the potential of P. amboinicus leaf extract in 
reducing inflammation in patients with GA has different 
mechanisms compared to NSAIDs (control group). 
Recently, the treatment of GA and other arthritis 
diseases developed based on anti-cytokine-based 
treatment by blockade of chemokine,7 inhibition of IL-
1β release8 and release of TNF-α inhibition.9-11 
However, to obtain high potency of the active 
compound P. amboinicus leaf extract requires a process 
of repetition ranging from isolation, processing, testing 
and pharmacological responses in experimental animals 
and patients with GA. 
 
Conclusions 
 
This study found that the levels of BUN and creatinine 
in the control group decreased, while there was an 
increase in the treatment group although not significant, 
but the BUN and creatinine levels of the two groups are 
remain within normal range. The concentration of TNF-
α in the control and treatment groups both decreased, 
but not significantly, while the concentration of IL-1β in 
the control group increased, but decreased in the 
treatment group, although not significant. Therefore, for 
patients with GA, P. amboinicus leaf extract capsules 
can be used as an additional medication to treat the 
disease, as evidenced during this study there was no 
significant complaints and patient felt more comfortable 
to drink the leaft extract capsule.  
 
Recommendations: Further studies could be developed 
by administering varying concentrations with a larger 
sample. 
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